This review synthesizes literature on how commonly prescribed medications—antihypertensives, statins, antidepressants, levothyroxine, proton pump inhibitors, phosphodiesterase type 5 inhibitors, and metformin—affect sleep. With many primary care patients reporting sleep issues and more than half of American adults using prescription medications, understanding these effects is essential. Methods included a comprehensive PubMed search of the past decade using relevant medication and sleep-related terms.

Hepatocellular carcinoma (HCC) is the second leading cause of global cancer-related death, and more than 80% of the global burden is borne by lower income countries.1 However, liver transplant (LT) and endovascular or percutaneous tumor destructive treatments provide cure rates approaching 90% at 5 years. Linkage to LT, rather than to chemotherapy, is therefore the standard of care for patients with nonmetastatic HCC, propelling HCC to the fourth leading indication for LT in the United States.2 However in lower income countries, in which the symphony of pretransplant medical optimization, tumor destructive treatments, organ procurement, transplant surgery, and lifelong posttransplant care is lacking, HCC management is often relegated to palliative therapy or no treatment at all.

Since the first successful human kidney transplant was performed between the identical twin brothers Ronald and Richard Herrick in 1954, solid organ transplantation has become established as a unique lifesaving and life-enhancing treatment for tens of thousands of children and adults worldwide each year. Iconic achievements in transplant surgery, immunology, and immune suppressive therapies marked the history of organ transplantation between the 1950s and 1990s, extending the benefits to patients with irreversible failure of kidneys, liver, heart, lungs, pancreas, and intestines and establishing short- and long-term success rates that readily justified the complexity and costs involved.

This year, Ravindra Ganesh, MBBS, MD, was honored with a Mayo Clinic Proceedings highly cited author award, which was developed to acknowledge articles for their meaningful contr ibution to the Journal’s Impact Factor. “These highly cited manuscripts received enough citations to place them in the top 1% of the academic field of clinical medicine based on a highly cited threshold for the field and publication year, contributing to Mayo Clinic Proceedings’ 2023 Impact Factor,” says Karl A. Nath, MB, ChB,